Engineered T cells: the promise and challenges of cancer immunotherapy.
about
Diacylglycerol Kinases in T Cell Tolerance and Effector FunctionCytotoxic CD4 T Cells: Differentiation, Function, and Application to Dengue Virus InfectionChimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor ImmunityGenomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.NK cells converge lytic granules to promote cytotoxicity and prevent bystander killing.Chimeric antigen receptor T cells: a novel therapy for solid tumors.How do i participate in T-cell immunotherapy?Multiplexing Engineered Receptors for Multiparametric Evaluation of Environmental Ligands.Reconstructing the immune system with lentiviral vectors.Manufacturing Cell Therapies Using Engineered Biomaterials.A Comparative Study of Clinical Intervention and Interventional Photothermal Therapy for Pancreatic Cancer.Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).Editing the genome of hiPSC with CRISPR/Cas9: disease models.The Individual and Population Genetics of Antibody Immunity.Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.Driving gene-engineered T cell immunotherapy of cancer.Synthetic Biology-The Synthesis of Biology.The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.Genome Editing Techniques and Their Therapeutic Applications.The revival of cancer vaccines - The eminent need to activate humoral immunity.Engineering HIV-Specific Immunity with Chimeric Antigen Receptors.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelCurrent status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Delivering safer immunotherapies for cancer.Transcriptional and epigenetic regulation of T cell hyporesponsiveness.Engineering challenges for brain tumor immunotherapy.Molecular imaging biomarkers for cell-based immunotherapies.Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.Fight fire with fire: Gene therapy strategies to cure HIV.Reprogramming cellular functions with engineered membrane proteins.Treating breast cancer with cell-based approaches: an overview.Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs.Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells.Tumor-specific hepatic stellate cells (tHSCs) induces DIgR2 expression in dendritic cells to inhibit T cells.
P2860
Q28079616-F6F70937-A2E3-44ED-A3AC-C82CCE2D8B0CQ28079626-AEC8E65F-0DFD-4069-97BE-894A70E7F744Q33700795-B155BE69-057F-4C9D-B0EA-1B5419BD3DFCQ33838679-41387A18-5F17-4BB3-81E3-CB970CC7459EQ37513964-FA545F37-B4B3-4822-85FA-77DBC46D8E50Q37728639-E1081B13-5A14-4C80-A4CE-431B4F00657EQ38371637-36D40406-45C6-43DC-8913-CDD90A310453Q38647622-FD7938A7-EE5F-4C0D-A44B-05A6BE22BEA7Q38651711-ED98AE71-56B5-44E2-A9AE-BC4C9C749838Q38657159-E926542A-13AD-4513-AEBC-ED3E0EF84C4DQ38662058-8782D955-2E20-4D92-A5AF-4E56D5CA3A4DQ38677432-1002B671-1A43-4A5B-9125-357CB706940DQ38681083-8FCC450F-F7C8-4DC5-8A5C-C80E457681C8Q38711908-01A578D5-1EAA-4E6A-9191-73A70E67B7F6Q38766578-FDBF3C71-2E1C-4432-B752-22721A5417DCQ38777005-E8032C79-DE00-45C0-B685-C41405064E63Q38777742-053BEBCA-C960-4BC0-A23D-A88EC87091FEQ38784006-A74CCF2D-1F39-4BA3-AA2A-45C4C82974EAQ38930113-BEFF0D0B-5B1A-4593-9A4E-B758C3B14646Q38991325-1A5AEDA6-88FE-4E67-BAC9-6D4C80ABF935Q39001905-039DC3BD-D8EF-4921-B61F-85DFEAB41246Q39025469-1C67777A-6EBC-4F94-841A-1F977D564208Q39130451-67F24AFF-0C69-4022-97DA-731B8523F5D3Q39243052-7BAF585D-AD08-49F1-AFA6-568FACFFD9FAQ39249589-E9DC70EA-70F6-4208-AA36-1ACDAA711451Q39280002-DFF7962D-6AC6-4927-A838-B630630AF78CQ39330984-DD39DC34-E2A7-4861-9A44-776CB804FF6CQ39367810-457AC76B-124C-4E14-AD31-92EB3474B292Q39381281-0DB71ADE-E044-4C7E-8468-044FB4EFF4ACQ39383670-FE6B391B-C570-49CA-915B-281A64E795C1Q39398719-93DEF5C7-72F7-40CF-8642-F8AF400223D1Q39425614-3743B9CB-ECBC-43C8-9D0A-651E2E09B653Q39435526-196780F9-6D78-4BFB-8E23-32C0DD6DCDB3Q39448180-3CE50EC3-01EA-4E1B-B405-2BDB259DDC96Q40044791-C6F6A778-D758-4988-A2C6-D4E37D0E9618Q40064246-1FD01732-D73C-40A7-B114-C02DAF5B0CC4Q40069479-41572161-8051-4955-880A-3D16A42F0B44Q40155189-D0D71B4C-8D6A-4B44-9E42-C67459CA1266Q40277804-C489BFFC-E145-4343-A827-0A610C19BBC8Q41549602-2525022A-440B-4A10-B1C5-17E2AA5321DC
P2860
Engineered T cells: the promise and challenges of cancer immunotherapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Engineered T cells: the promise and challenges of cancer immunotherapy.
@en
type
label
Engineered T cells: the promise and challenges of cancer immunotherapy.
@en
prefLabel
Engineered T cells: the promise and challenges of cancer immunotherapy.
@en
P2860
P356
P1476
Engineered T cells: the promise and challenges of cancer immunotherapy
@en
P2093
Bruce L Levine
Carl H June
P2860
P2888
P304
P356
10.1038/NRC.2016.97
P407
P577
2016-08-01T00:00:00Z
P6179
1035557088